Publications by authors named "L Tandaric"

Claim this Profile
P
Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti-CD73/anti-PD-L1 immunotherapy in arm A of the NSGO-OV-UMB1/ENGOT-OV30 trial.
Luka Tandaric, Annika Auranen, Katrin Kleinmanns, René DePont Christensen, Liv Cecilie Vestrheim Thomsen

Mol Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma.
Leo Meriranta, Selma Sorri, Kanutte Huse, Xiaonan Liu, Ivana Spasevska

Blood Cancer Discov· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer.
M R Mirza, L Tandaric, J R Henriksen, J Mäenpää, R D Christensen

Gynecol Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia.
Benjamin Caulier, Sandy Joaquina, Pascal Gelebart, Tara Helén Dowling, Fatemeh Kaveh, Luka Tandaric

Cell Rep Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis